The impact of the COVID-19 pandemic on chlamydia infection in South Korea: a comparison between the pre-pandemic and during-pandemic periods.
Korea
SARS-CoV-2
chlamydia
sexually transmitted disease (STD)
sexually transmitted infection (STI)
surveillance
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
02
2023
accepted:
29
03
2023
medline:
29
5
2023
pubmed:
25
5
2023
entrez:
25
5
2023
Statut:
epublish
Résumé
Prior to COVID-19 pandemic, a yearly upward trajectory in the number of chlamydia infection cases was observed in South Korea. However, in response to the COVID-19 pandemic, Korea implemented several public health and social measures, which were shown to have an impact on the epidemiology of other infectious diseases. This study aimed to estimate the impact of the COVID-19 pandemic on the incidence and number of reported chlamydia infections in South Korea. Using the monthly number of reported chlamydia infection data between 2017 and 2022, we compared the trends in the reported numbers, and the incidence rates (IR) of chlamydia infection stratified by demographic characteristics (sex, age group, and region) in the pre- and during COVID-19 pandemic period (January 2017-December 2019 and January 2020-December 2022). We observed an irregular downward trajectory in the number of chlamydia infection in the during-pandemic period. A 30% decrease in the total number of chlamydia infection was estimated in the during-pandemic compared to the pre-pandemic period, with the decrease greater among males (35%) than females (25%). In addition, there was a decrease in the cumulative incidence rate of the during COVID-19 pandemic period (IR: 0.43; 95% CI: 0.42-0.44) compared to the pre-pandemic period (IR: 0.60; 95% CI: 0.59-0.61). We identified decrease in the number of chlamydia infection during COVID-19 pandemic which is likely due to underdiagnosis and underreporting for the infection. Therefore, strengthening surveillance for sexually transmitted infections including chlamydia is warranted for an effective and timely response in case of an unexpected rebound in the number of the infections.
Sections du résumé
Background
Prior to COVID-19 pandemic, a yearly upward trajectory in the number of chlamydia infection cases was observed in South Korea. However, in response to the COVID-19 pandemic, Korea implemented several public health and social measures, which were shown to have an impact on the epidemiology of other infectious diseases. This study aimed to estimate the impact of the COVID-19 pandemic on the incidence and number of reported chlamydia infections in South Korea.
Methods
Using the monthly number of reported chlamydia infection data between 2017 and 2022, we compared the trends in the reported numbers, and the incidence rates (IR) of chlamydia infection stratified by demographic characteristics (sex, age group, and region) in the pre- and during COVID-19 pandemic period (January 2017-December 2019 and January 2020-December 2022).
Results
We observed an irregular downward trajectory in the number of chlamydia infection in the during-pandemic period. A 30% decrease in the total number of chlamydia infection was estimated in the during-pandemic compared to the pre-pandemic period, with the decrease greater among males (35%) than females (25%). In addition, there was a decrease in the cumulative incidence rate of the during COVID-19 pandemic period (IR: 0.43; 95% CI: 0.42-0.44) compared to the pre-pandemic period (IR: 0.60; 95% CI: 0.59-0.61).
Conclusions
We identified decrease in the number of chlamydia infection during COVID-19 pandemic which is likely due to underdiagnosis and underreporting for the infection. Therefore, strengthening surveillance for sexually transmitted infections including chlamydia is warranted for an effective and timely response in case of an unexpected rebound in the number of the infections.
Identifiants
pubmed: 37228722
doi: 10.3389/fpubh.2023.1167321
pmc: PMC10203704
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1167321Informations de copyright
Copyright © 2023 Chiara, Ryu, Jung and Hwang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Open Forum Infect Dis. 2022 Jul 01;9(7):ofac322
pubmed: 35899288
Sex Transm Dis. 2021 Oct 1;48(10):798-804
pubmed: 34224523
Can Commun Dis Rep. 2018 Feb 01;44(2):49-54
pubmed: 29770099
Lancet Glob Health. 2022 Nov;10(11):e1612-e1622
pubmed: 36240828
Sex Transm Infect. 2022 Mar;98(2):155
pubmed: 34088791
J Eur Acad Dermatol Venereol. 2021 Mar;35(3):e171-e172
pubmed: 33078481
J Infect Public Health. 2020 Aug;13(8):1112-1117
pubmed: 32471797
Emerg Infect Dis. 2020 Oct;26(10):2406-2410
pubmed: 32487283
Sex Transm Dis. 2022 Jul 1;49(7):490-496
pubmed: 35470348
Gut Liver. 2022 Jan 15;16(1):81-91
pubmed: 34238769
APMIS. 2022 Jan;130(1):34-42
pubmed: 34758169
J Prev Med Public Health. 2020 May;53(3):164-167
pubmed: 32498138
Sex Transm Dis. 2021 Jan;48(1):e5-e7
pubmed: 33181578
BMC Infect Dis. 2019 Jan 8;19(1):31
pubmed: 30621621
Sex Transm Dis. 2021 Aug 1;48(8):606-613
pubmed: 33859146
J Travel Med. 2020 Dec 23;27(8):
pubmed: 32841356
J Clin Outcomes Manag. 2014 Jan;21(1):30-38
pubmed: 25554725
Viruses. 2022 May 17;14(5):
pubmed: 35632810
BMJ. 2020 Apr 27;369:m1557
pubmed: 32341002
Infect Dis (Lond). 2022 Sep;54(9):623-631
pubmed: 35527677
Public Health. 2023 Jan;214:20-24
pubmed: 36436277
Sex Transm Infect. 2021 Dec;97(8):622-623
pubmed: 33574133
Sex Transm Dis. 2020 Jul;47(7):427-430
pubmed: 32541302
Sex Transm Infect. 2021 Nov;97(7):550
pubmed: 33397798
Sex Transm Infect. 2021 Mar;97(2):101-102
pubmed: 33132224
Sex Transm Infect. 2021 Nov;97(7):501-506
pubmed: 34045364
Sex Transm Infect. 2022 Feb;98(1):70
pubmed: 33653880